Low rate of resistance, with only 1.6% of participants developing resistance to any study drug through W48

DOR/3TC/TDF was generally well tolerated and safe:

Neuropsychiatric profile superior to EFV/FTC/TDF, as measured by lower proportion of participants with neuropsychiatric adverse events in categories of dizziness, sleep disorders and disturbances, and altered sensorium

Lipid profile superior to EFV/FTC/TDF, as assessed by difference from baseline in fasting LDL-C and non-HDL-C